Future Trends and Emerging Applications in Metabolomics

A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Nutrition and Metabolism".

Deadline for manuscript submissions: 15 April 2025 | Viewed by 1489

Special Issue Editors


E-Mail Website
Guest Editor
Centre for Advanced Medical and Pharmaceutical Research, “George Emil Palade” University of Medicine, Pharmacy, Science and Technology of Târgu Mures, 38 Gheorghe Marinescu Street, 540142 Targu Mures, Romania
Interests: bioanalysis; metabolomics; LC-MS; pharmaceuticals; nutritional supplements; fitopharmacy; pharmacokinetics; pharmacodynamics; pesticides

E-Mail Website
Guest Editor
Faculty of Veterinary Medicine, University of Life Sciences “King Mihai I” from Timisoara, Calea Aradului, No. 119, 300645 Timisoara, Romania
Interests: animal nutrition; nutrients; metabolism; nutritional supplements; biomolecules; enzymes; nutrient absorption

E-Mail Website
Guest Editor
Department of Medicinal Chemistry, University of Florida, Gainesville, FL 32610, USA
Interests: carcinogen metabolism and carcinogenesis; metabolite-based biomarkers; mass spectrometry; bioanalytical chemistry

Special Issue Information

Dear Colleagues,

We propose a Special Issue for the Journal Metabolites regarding metabolomics studies, including current and future trends, situated within the following current fields of studies: biological metabolites used as biomarkers for disease diagnostics; drug metabolism studies with a focus on metabolite interactions; novel bioanalytical approaches in the bioanalysis of biological and drug metabolism; advances in vivo study design (animal and human model) in metabolomics; study of nutraceuticals and nutrient metabolism; catabolism studies.

Liquid chromatography coupled with mass spectrometry, as one of the most powerful and widely used methods in the field of metabolomics studies, as well as the main field of study of one of the guest authors, will be the main focus of this Special Issue, but other types of bioanalytical methods are also of interest. Although the main focus in the field of metabolomics is on in vivo studies, interesting in-vitro studies with ramifications in the study of metabolic pathways could also be welcomed.

Dr. Lenard Farczadi
Dr. Ionela Hotea
Prof. Dr. Chengguo Xing
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • metabolomics
  • metabolism
  • interaction studies
  • pharmacokinetics
  • bioavailability
  • mass spectrometry
  • bioanalysis
  • biomarkers
  • nutrients
  • animal studies enzymes

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 987 KiB  
Article
Bupropion Increased More than Five Times the Systemic Exposure to Aripiprazole: An In Vivo Study in Wistar albino Rats
by Iulia-Maria Ciocotișan, Dana Maria Muntean and Laurian Vlase
Metabolites 2024, 14(11), 588; https://doi.org/10.3390/metabo14110588 - 30 Oct 2024
Viewed by 1105
Abstract
Background/Objectives: In psychiatric disorders, antipsychotics and antidepressant medication are often administered together. Aripiprazole, a third-generation antipsychotic drug, is extensively metabolized by CYP2D6 and CYP3A4 isoenzymes, while bupropion, used in depressive disorders, is known as a moderate or strong CYP2D6 enzyme inhibitor. This [...] Read more.
Background/Objectives: In psychiatric disorders, antipsychotics and antidepressant medication are often administered together. Aripiprazole, a third-generation antipsychotic drug, is extensively metabolized by CYP2D6 and CYP3A4 isoenzymes, while bupropion, used in depressive disorders, is known as a moderate or strong CYP2D6 enzyme inhibitor. This in vivo experiment aimed to assess the presence of a pharmacokinetic drug interaction between aripiprazole and bupropion and its magnitude on the systemic exposure of aripiprazole. Methods: 24 healthy Wistar albino male rats were included in two study groups. A single dose of 8 mg/kg aripiprazole was given to rats in the reference group, while the test group received repeated doses of bupropion for 6 days, followed by a single dose of aripiprazole. An LC-MS/MS method was developed for the concomitant quantification of aripiprazole and its active metabolite, dehydroaripiprazole, and non-compartmental analysis was employed to assess their pharmacokinetic parameters. Results: The mean AUC0-∞ of aripiprazole increased 5.65-fold (1117.34 ± 931.41 vs. 6311.66 ± 2978.71 hr·ng/mL), the mean Cmax increased by 96.76% and the apparent systemic clearance decreased over 9-fold after bupropion repeated doses. The exposure to aripiprazole’s active metabolite increased as well, having a 4-fold increase in the mean AUC0–∞ (from 461.13 ± 339.82 to 1878.66 ± 1446.91 hr·ng/mL) and a 2-fold increase in the mean Cmax. Conclusions: The total exposure to the aripiprazole parent compound and active moiety significantly increased after bupropion pretreatment in this preclinical in vivo experiment. Clinical studies should further establish the significance of this interaction in humans. Full article
(This article belongs to the Special Issue Future Trends and Emerging Applications in Metabolomics)
Show Figures

Figure 1

Back to TopTop